Anebulo Pharmaceuticals Inc (ANEB)

$0.43 +0.07 (20.64%)
Market Cap 14.68M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,400
Avg Vol 120,658
Day's Range N/A - N/A
Shares Out 40.79M
Stochastic %K 44%
Beta -0.81
Analysts Sell
Price Target $3.00

Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceut...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 598 0931
Address:
1017 Ranch Road 620 South, Suite 107, Lakeway, United States
Whiskey1679
Whiskey1679 Mar. 1 at 4:54 PM
Whiskey Penny Picks out tomorrow. Any great cheap oil, defense/drone type stocks? Hit me up!! Might pick 'em tomorrow morning!! AH Gainers/trending a bit: $ELPW $LRHC $ANEB $INUV $BGL
2 · Reply
focafoca99
focafoca99 Feb. 28 at 7:21 AM
$ANEB confirmed, delisted this Monday. to quote in OTC
0 · Reply
focafoca99
focafoca99 Feb. 26 at 10:59 PM
$ANEB should be delisted today, right?
0 · Reply
AgnesLange304
AgnesLange304 Feb. 21 at 9:03 AM
$ANEB Anebulo Pharmaceuticals develops addiction therapies. Clinical milestones drive valuation. Early-stage risk remains.
0 · Reply
peepthestamp
peepthestamp Feb. 18 at 4:15 PM
$ANEB
0 · Reply
BasisTrading
BasisTrading Feb. 17 at 1:25 PM
$ANEB Pre-revenue biotech; early-stage.
0 · Reply
d_risk
d_risk Feb. 12 at 10:41 PM
$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB flags ongoing zero revenue, a $78M accumulated deficit, rising R&D spend for clinical trials, and uncertainty about securing funding, warning it may need to scale back operations and may never reach profitability even after going private. #Pharmaceuticals #R&DSpending #FinancialRisk #FundingUncertainty #OperationalScaling 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2026-02-12
0 · Reply
Stockinvestor73
Stockinvestor73 Feb. 9 at 3:49 PM
$ANEB Hoe low can it go?
0 · Reply
DipDiverPro
DipDiverPro Feb. 9 at 3:31 PM
$ANEB Biotech or pharmaceutical; name not standard, indicating high risk.
0 · Reply
Bigstud98
Bigstud98 Feb. 8 at 6:24 AM
$ANEB BEARISH!
0 · Reply
Latest News on ANEB
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Feb 12, 2026, 4:15 PM EST - 18 days ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Feb 6, 2026, 9:00 AM EST - 25 days ago

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Jan 29, 2026, 9:00 AM EST - 4 weeks ago

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Jan 27, 2026, 9:00 AM EST - 5 weeks ago

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Dec 22, 2025, 9:00 AM EST - 2 months ago

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Nov 13, 2025, 4:05 PM EST - 3 months ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Sep 29, 2025, 4:05 PM EDT - 5 months ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Sep 25, 2025, 7:30 AM EDT - 5 months ago

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Sep 12, 2025, 7:30 AM EDT - 6 months ago

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

May 13, 2025, 4:05 PM EDT - 10 months ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Feb 14, 2025, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Dec 23, 2024, 9:15 AM EST - 1 year ago

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Sep 25, 2024, 4:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

May 15, 2024, 1:15 PM EDT - 1 year ago

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

May 15, 2024, 1:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024, 4:05 PM EST - 2 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023, 4:05 PM EST - 2 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Anebulo Pharmaceuticals Announces New CEO

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces New CEO

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Sep 20, 2023, 4:29 PM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Mar 8, 2023, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Feb 10, 2023, 8:38 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Jan 27, 2023, 3:49 PM EST - 3 years ago

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Jan 9, 2023, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Nov 10, 2022, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Nov 1, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Sep 20, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Sep 9, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Aug 23, 2022, 5:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Jul 5, 2022, 6:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Jun 23, 2022, 4:00 PM EDT - 4 years ago

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

May 24, 2022, 4:00 PM EDT - 4 years ago

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022, 9:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Apr 1, 2022, 7:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Feb 11, 2022, 9:13 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Feb 11, 2022, 8:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Jan 6, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 6, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Jan 4, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Jan 3, 2022, 7:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Nov 12, 2021, 8:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Whiskey1679
Whiskey1679 Mar. 1 at 4:54 PM
Whiskey Penny Picks out tomorrow. Any great cheap oil, defense/drone type stocks? Hit me up!! Might pick 'em tomorrow morning!! AH Gainers/trending a bit: $ELPW $LRHC $ANEB $INUV $BGL
2 · Reply
focafoca99
focafoca99 Feb. 28 at 7:21 AM
$ANEB confirmed, delisted this Monday. to quote in OTC
0 · Reply
focafoca99
focafoca99 Feb. 26 at 10:59 PM
$ANEB should be delisted today, right?
0 · Reply
AgnesLange304
AgnesLange304 Feb. 21 at 9:03 AM
$ANEB Anebulo Pharmaceuticals develops addiction therapies. Clinical milestones drive valuation. Early-stage risk remains.
0 · Reply
peepthestamp
peepthestamp Feb. 18 at 4:15 PM
$ANEB
0 · Reply
BasisTrading
BasisTrading Feb. 17 at 1:25 PM
$ANEB Pre-revenue biotech; early-stage.
0 · Reply
d_risk
d_risk Feb. 12 at 10:41 PM
$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB flags ongoing zero revenue, a $78M accumulated deficit, rising R&D spend for clinical trials, and uncertainty about securing funding, warning it may need to scale back operations and may never reach profitability even after going private. #Pharmaceuticals #R&DSpending #FinancialRisk #FundingUncertainty #OperationalScaling 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2026-02-12
0 · Reply
Stockinvestor73
Stockinvestor73 Feb. 9 at 3:49 PM
$ANEB Hoe low can it go?
0 · Reply
DipDiverPro
DipDiverPro Feb. 9 at 3:31 PM
$ANEB Biotech or pharmaceutical; name not standard, indicating high risk.
0 · Reply
Bigstud98
Bigstud98 Feb. 8 at 6:24 AM
$ANEB BEARISH!
0 · Reply
HatimIsHere
HatimIsHere Feb. 7 at 9:24 PM
$ANEB Anebulo Pharmaceuticals will voluntarily delist its common stock from the Nasdaq Stock Market, effective February 27, 2026, after its number of shareholders fell below 300. The decision was officially announced on February 6, 2026, and will terminate the company’s reporting obligations with the U.S. Securities and Exchange Commission (SEC).
1 · Reply
Stockinvestor73
Stockinvestor73 Feb. 7 at 7:33 PM
$ANEB what's everyone's take on the buyout price to go private...... Debating whether i should take a position here before it goes to the otc
0 · Reply
UgoGreg
UgoGreg Feb. 7 at 3:27 PM
$ANEB https://youtu.be/ygBN8MilTyc
0 · Reply
Stockinvestor73
Stockinvestor73 Feb. 7 at 2:51 PM
$ANEB have they communicated a buyout ricgorivate?
0 · Reply
UgoGreg
UgoGreg Feb. 6 at 5:54 PM
$ANEB https://youtu.be/AJ5U-pgHZEo
0 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 5:24 PM
$ADAPY $ANEB completely different situation
0 · Reply
Stockinvestor73
Stockinvestor73 Feb. 6 at 4:43 PM
$ADAPY I guess nobody is going to want @ANEB as well since thyare going to the OTC. Not even the insiders wold want it despite the PR and hopes to go private?... why don't you go short $ANEB?
0 · Reply
Stockinvestor73
Stockinvestor73 Feb. 6 at 2:14 PM
$ADAPY Looks like we started a trend. $ANEB is delisting as well......
0 · Reply
TwongStocks
TwongStocks Feb. 6 at 2:14 PM
$ANEB Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC https://www.businesswire.com/news/home/20260206485482/en/Anebulo-Pharmaceuticals-Announces-Intention-to-Voluntarily-Delist-from-Nasdaq-and-Deregister-with-SEC Form 25 anticipated to be filed Feb 17 with delisting expected Feb 27. "Following the delisting, any trading in Anebulo’s common stock would only occur in privately negotiated sales and potentially on the over-the-counter market. "
0 · Reply
DummiesNixGerafft
DummiesNixGerafft Feb. 4 at 7:58 PM
Die aktuellen Raketen $GUTS $LITS $ASMB $ANEB
1 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:45 PM
$ANEB avg price target is between 5-8$ bullish long term.
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 31 at 1:44 PM
$ANEB The company’s lack of debt provides flexibility to fund operations and R&D without heavy interest burdens, a plus for clinical-stage biotech firms that often spend years without revenue.
0 · Reply